ATE170746T1 - Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten - Google Patents

Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten

Info

Publication number
ATE170746T1
ATE170746T1 AT92912379T AT92912379T ATE170746T1 AT E170746 T1 ATE170746 T1 AT E170746T1 AT 92912379 T AT92912379 T AT 92912379T AT 92912379 T AT92912379 T AT 92912379T AT E170746 T1 ATE170746 T1 AT E170746T1
Authority
AT
Austria
Prior art keywords
receptor agonists
tetrahydrocarbazole derivatives
tetrahydrocarbazole
derivatives
agonists
Prior art date
Application number
AT92912379T
Other languages
German (de)
English (en)
Inventor
Francis David King
Laramie Mary Gaster
Alberto Julio Kaumann
Rodney Christopher Young
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE170746(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE170746T1 publication Critical patent/ATE170746T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92912379T 1991-06-26 1992-06-17 Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten ATE170746T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments

Publications (1)

Publication Number Publication Date
ATE170746T1 true ATE170746T1 (de) 1998-09-15

Family

ID=10697363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912379T ATE170746T1 (de) 1991-06-26 1992-06-17 Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten

Country Status (34)

Country Link
US (2) US5464864A (https=)
EP (1) EP0591280B1 (https=)
JP (1) JP3261502B2 (https=)
KR (1) KR100251571B1 (https=)
CN (1) CN1034072C (https=)
AP (1) AP344A (https=)
AT (1) ATE170746T1 (https=)
BR (2) BR9206237A (https=)
CA (1) CA2113726C (https=)
CZ (3) CZ282327B6 (https=)
DE (2) DE69226953T2 (https=)
DK (1) DK0591280T3 (https=)
FI (1) FI103967B1 (https=)
GB (1) GB9113802D0 (https=)
HU (1) HU218907B (https=)
IE (1) IE922062A1 (https=)
IL (4) IL117105A (https=)
LU (1) LU90939I2 (https=)
MA (1) MA22563A1 (https=)
MX (1) MX9203444A (https=)
NL (1) NL300103I2 (https=)
NO (2) NO304774B1 (https=)
NZ (1) NZ243288A (https=)
PL (3) PL169392B1 (https=)
PT (1) PT100620B (https=)
RU (1) RU2137474C1 (https=)
SA (1) SA92130141B1 (https=)
SG (1) SG47877A1 (https=)
SI (1) SI9200125B (https=)
SK (3) SK280906B6 (https=)
TW (1) TW214544B (https=)
UA (1) UA41254C2 (https=)
WO (1) WO1993000086A1 (https=)
ZA (1) ZA924658B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
EP0749962B1 (en) * 1995-06-23 2000-11-02 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
WO2003029214A1 (en) * 2001-09-28 2003-04-10 F. Hoffmann-La Roche Ag Pseudopolymorphic forms of carvedilol
BR0312176A (pt) 2002-06-21 2005-04-05 Suven Life Sciences Ltd Composto, composição farmaceutica, uso de um composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso, processo para a preparação de um composto, novo intermediario e processo para a preparação de um novo intermediario
AU2003249584B9 (en) 2002-06-21 2008-05-15 Suven Life Sciences Limited Arylalkyl indoles having sertonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
BRPI0315959C1 (pt) 2002-11-28 2021-05-25 Suven Life Sciences Ltd composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto
PT1567492E (pt) 2002-11-28 2013-07-22 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxi-indóis
DK1581538T3 (da) 2002-12-18 2007-06-25 Suven Life Sciences Ltd Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet
RU2430088C2 (ru) * 2004-07-14 2011-09-27 Центарис Гмбх Производные тетрагидрокарбазола и фармацевтическая композиция на их основе
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators
BRPI0715179A2 (pt) * 2006-08-07 2013-06-11 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
DK2425820T3 (en) 2007-02-11 2015-07-13 Map Pharmaceuticals Inc A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
WO2011050140A1 (en) 2009-10-22 2011-04-28 Blue Fury Consulting, L.L.C. Posterior cervical fusion system and techniques
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
EP3628325A1 (en) 2011-07-22 2020-04-01 The University of Chicago Treatments for migraine and related disorders
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
EP2816030A1 (en) 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
AU2024326262A1 (en) * 2023-08-13 2026-03-26 GATC Health Corp Compounds and methods for treating addiction
CN119499195A (zh) * 2024-11-26 2025-02-25 青岛国信制药有限公司 一种快速吸收琥珀酸呋罗曲坦片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US3959309A (en) 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4172834A (en) * 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
CZ282061B6 (cs) 1997-05-14
FI935842A7 (fi) 1993-12-23
IL117104A0 (en) 1996-06-18
IL117105A (en) 1998-01-04
SK131993A3 (en) 1994-06-08
US5637611A (en) 1997-06-10
MA22563A1 (fr) 1992-12-31
IE922062A1 (en) 1992-12-30
US5464864A (en) 1995-11-07
GB9113802D0 (en) 1991-08-14
DE10299042I1 (de) 2003-02-20
IL102322A (en) 1997-09-30
SI9200125B (en) 2001-12-31
FI103967B (fi) 1999-10-29
PT100620A (pt) 1993-09-30
AU652842B2 (en) 1994-09-08
IL102322A0 (en) 1993-01-14
BR1100460A (pt) 2000-07-18
TW214544B (https=) 1993-10-11
DE69226953T2 (de) 1999-05-12
NL300103I2 (nl) 2003-02-03
WO1993000086A1 (en) 1993-01-07
HU218907B (hu) 2000-12-28
PL169392B1 (pl) 1996-07-31
EP0591280B1 (en) 1998-09-09
AP344A (en) 1994-07-05
CZ282083B6 (cs) 1997-05-14
LU90939I2 (fr) 2002-09-24
UA41254C2 (uk) 2001-09-17
SA92130141B1 (ar) 2005-12-18
FI103967B1 (fi) 1999-10-29
NO304774B1 (no) 1999-02-15
NO934800L (no) 1993-12-23
AU1977592A (en) 1993-01-25
CA2113726C (en) 2008-02-19
NZ243288A (en) 1994-09-27
PL171034B1 (en) 1997-02-28
CZ150696A3 (en) 1997-06-11
JP3261502B2 (ja) 2002-03-04
DK0591280T3 (da) 1999-02-15
PT100620B (pt) 1999-01-29
IL117104A (en) 1997-09-30
SG47877A1 (en) 1998-04-17
ZA924658B (en) 1993-12-24
SI9200125A (en) 1992-12-31
SK280906B6 (sk) 2000-09-12
DE10299042I2 (de) 2005-02-03
HK1014669A1 (en) 1999-09-30
JPH06508827A (ja) 1994-10-06
KR100251571B1 (ko) 2000-07-01
PL169410B1 (pl) 1996-07-31
BR9206237A (pt) 1995-04-11
NL300103I1 (nl) 2002-12-02
HUT68961A (en) 1995-08-28
CZ282327B6 (cs) 1997-06-11
NO934800D0 (no) 1993-12-23
DE69226953D1 (de) 1998-10-15
FI935842A0 (fi) 1993-12-23
SK280907B6 (sk) 2000-09-12
AP9200403A0 (en) 1992-07-31
CZ150596A3 (en) 1997-05-14
NO2005011I1 (no) 2005-05-18
CZ286193A3 (en) 1994-07-13
CN1034072C (zh) 1997-02-19
RU2137474C1 (ru) 1999-09-20
NO2005011I2 (no) 2008-02-11
CA2113726A1 (en) 1993-01-07
CN1069726A (zh) 1993-03-10
MX9203444A (es) 1993-12-01
IL117105A0 (en) 1996-06-18
EP0591280A1 (en) 1994-04-13
SK280905B6 (sk) 2000-09-12

Similar Documents

Publication Publication Date Title
DE10299042I1 (de) Verwendung von tetrahydrocarbazolderivaten als 5ht1-Rezeptoragonisten
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
KR950700906A (ko) 5-ht1 작동약으로서의 인돌 유도체(indole derivatives as 5-ht1 agonists)
FI914065A7 (fi) Serotoniini-5HT1A-agonisteja
ATE180785T1 (de) Kondensierte indol-derivate als 5-ht4-rezeptor- antagonisten
FI922481A7 (fi) Heterosyklisiä johdannaisia
DE69431880D1 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
FI944805A7 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina
FI904591A7 (fi) Heterosyklisiä johdannaisia
FI942635A7 (fi) Piperatsiinijohdannaiset 5HT1A-antagonisteina
ATE222492T1 (de) Verwendung von indolderivaten als 5ht1-agonisten
DE69401823D1 (de) Indolin derivate als 5ht2c antagonisten
DE69220382D1 (de) Verwendung von Peptidderivaten
FI961628A0 (fi) Indolijohdannaisia NMDA-antagonisteina
DE69418045D1 (de) Amidderivate als 5ht1d rezeptor antagonisten
ATE210659T1 (de) Indolalkylderivate von benzodioxanmenthylamin als 5-ht1a rezeptor liganden
FI944727L (fi) Indolijohdannaisia 5-HT1:n kaltaisina agonisteina
DE69320653D1 (de) Tetrahydrocarbazolderivate als 5-ht1-ähnliche agonisten
FI923968A7 (fi) Heterosyklisesti substituoidut kinolyylimetoksifenyyliasetamidit
FI894491A7 (fi) Antihypertensiivisinä aineina käytettäviä uusia substituoituja tienopyraaneja
DE58903912D1 (de) Verwendung von 2-substituierten ethansulfonverbindungen als galvanotechnische hilfsstoffe.
DE59508900D1 (de) Verwendung von Dibrom-thiophen-carbonsäure-Derivaten als Mikrobizide
FI915026A7 (fi) 2-(substituoitu pyrrolidinyylitio)karbapeneemijohdannaisia
DE3881270D1 (de) Verwendung von pyrrolidon-derivaten als antiamnetikum.
DE3888727D1 (de) Verwendung von Äthylamin-Derivaten als antihypertensive Wirkstoffe.